UK Medtech Ponders Future As New Government Gets Up To Speed
Executive Summary
Post-Brexit concerns abound for UK medtech companies who are hoping that a renewed government focus on the life sciences industry will provide the support and benefits it needs amid the uncertainties brought on by the UK vote to leave the European Union.
You may also be interested in...
Brexit Reflections For UK IVDs: Harmonized Regulation, Staff Issues Key
The UK in vitro diagnostics industry has been working on two initiatives that set out its views on how to secure a stable and competitive future for the national industry in the months following the country's vote to leave the EU.
UK Medtech Presses For Federation Structure In Post-Brexit Environment
A national federation of medtech associations is being proposed by parts of the UK industry, which often feels muscled out of the debate by pharma for big issues like handling the country's exit from the EU. The argument is that a less fragmented sector voice would have more influence on government decisions.
George Freeman Departure Leaves UK Life Sciences Holding Its Breath
Theresa May has re-structured the Department of Health ministerial team as part of her wide-ranging reshuffle and in so doing moved life sciences minister George Freeman over to chair the prime minister’s policy board. The British biopharma community says it hopes he will be replaced – and soon.